Browse Studies — Arctuva

Phase 1

Phase 1 /2 Multicenter, Basket, Imaging Study Investigating the Safety and Diagnostic Performance of RYZ711 in Men With Prostate Cancer.

This is a Phase 1/2 multicenter, multi-cohort imaging study to evaluate the safety, tolerability, and diagnostic performance of RYZ711 positron emission tomogr…

Prostate Cancer (Adenocarcinoma)Adenocarcinoma of the ProstateMetastatic Castration-resistant Prostate Cancer (mCRPC)+3 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

RayzeBio, Inc.NCT07862582

Phase 1

Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy

This study compares two different imaging procedures to each other, one using positron emission tomography (PET) with fluorothymidine F-18 (FLT) (FLT PET for s…

Metastatic Castration-resistant Prostate Cancer

Estimated

~$150 – $3,000

Actual pay is set by the research site.

University of Wisconsin, MadisonNCT07609225

Phase 1

An Open-label, Multi-center, First in Human Phase I Global Dose Escalation and Expansion Study of INR731 Single Agent or in Combination With an Androgen Receptor Pathway Inhibitor in Patients With Metastatic Prostate Cancer

The purpose of this study is to assess the safety, tolerability, pharmacokinetics/pharmacodynamics, preliminary anti-tumor activity, and recommended dose of IN…

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Novartis PharmaceuticalsNCT07570979